Market Overview

From Earlier: Optimer, AstraZeneca Collaborate to Commercialize Fidaxomicin for Clostridium Difficile Infection in LatAm

Share:
Related OPTR
HSR Waiting Period Expires for Cubist, Optimer Deal
Cubist Pharma Reports Pricing of $700M in Convertible Senior Notes, Expecting Proceeds of $679M
Related AZN
US Stock Futures Tumble, China's Shanghai Plunges 8.5%
AstraZeneca, Peregrine Pharmaceuticals to Collaborate on Immuno-Oncology Combination Clinical Trial
Eli Lilly's (LLY) Diabetes Drug Synjardy Gets U.S. Approval (Zacks)

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today the execution of an exclusive agreement with AstraZeneca (NYSE: AZN) to commercialize fidaxomicin tablets for the treatment of Clostridium difficile Infection (CDI) in South America, including Brazil, Central America, Mexico and the Caribbean.

Under the terms of the agreement AstraZeneca is responsible for the commercialization of fidaxomicin in the territory covered by the collaboration and Optimer is entitled to receive an up-front payment of $1 million, up to $3 million in milestone payments upon first commercial sale in certain countries, and up to $19 million in other milestone payments contingent on the achievement of sales-related targets for fidaxomicin in the territory. Optimer is further entitled to receive payments from AstraZeneca that provide a return resulting in a double digit percent of net sales in the territory under a fidaxomicin supply agreement.

Posted-In: News

 

Related Articles (OPTR + AZN)

Get Benzinga's Newsletters